X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs GLENMARK PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. GLENMARK PHARMA WOCKHARDT LTD./
GLENMARK PHARMA
 
P/E (TTM) x -15.8 12.2 - View Chart
P/BV x 2.6 3.2 80.3% View Chart
Dividend Yield % 1.3 0.4 340.0%  

Financials

 WOCKHARDT LTD.   GLENMARK PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
GLENMARK PHARMA
Mar-17
WOCKHARDT LTD./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,129993 113.7%   
Low Rs627729 86.0%   
Sales per share (Unadj.) Rs363.1325.5 111.6%  
Earnings per share (Unadj.) Rs-20.439.3 -52.0%  
Cash flow per share (Unadj.) Rs-7.048.7 -14.3%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.10.2 490.4%  
Book value per share (Unadj.) Rs301.8159.2 189.6%  
Shares outstanding (eoy) m110.55282.17 39.2%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x2.42.6 91.4%   
Avg P/E ratio x-42.921.9 -195.9%  
P/CF ratio (eoy) x-125.917.7 -711.3%  
Price / Book Value ratio x2.95.4 53.8%  
Dividend payout %-48.95.1 -960.9%   
Avg Mkt Cap Rs m97,063242,991 39.9%   
No. of employees `0006.813.0 52.2%   
Total wages/salary Rs m9,66516,408 58.9%   
Avg. sales/employee Rs Th5,931.87,083.9 83.7%   
Avg. wages/employee Rs Th1,428.11,265.4 112.9%   
Avg. net profit/employee Rs Th-334.0855.1 -39.1%   
INCOME DATA
Net Sales Rs m40,14691,857 43.7%  
Other income Rs m1,143374 305.8%   
Total revenues Rs m41,28992,230 44.8%   
Gross profit Rs m12820,367 0.6%  
Depreciation Rs m1,4892,644 56.3%   
Interest Rs m2,2532,373 94.9%   
Profit before tax Rs m-2,47215,724 -15.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m-2113,827 -5.5%   
Profit after tax Rs m-2,26011,088 -20.4%  
Gross profit margin %0.322.2 1.4%  
Effective tax rate %8.524.3 35.1%   
Net profit margin %-5.612.1 -46.6%  
BALANCE SHEET DATA
Current assets Rs m46,16068,746 67.1%   
Current liabilities Rs m19,25827,027 71.3%   
Net working cap to sales %67.045.4 147.5%  
Current ratio x2.42.5 94.2%  
Inventory Days Days10185 118.5%  
Debtors Days Days9496 98.4%  
Net fixed assets Rs m40,16524,132 166.4%   
Share capital Rs m553282 195.9%   
"Free" reserves Rs m32,81444,643 73.5%   
Net worth Rs m33,36744,925 74.3%   
Long term debt Rs m31,90345,363 70.3%   
Total assets Rs m89,687117,639 76.2%  
Interest coverage x-0.17.6 -1.3%   
Debt to equity ratio x1.01.0 94.7%  
Sales to assets ratio x0.40.8 57.3%   
Return on assets %011.4 -0.1%  
Return on equity %-6.824.7 -27.4%  
Return on capital %-0.319.1 -1.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,12156,152 16.2%   
Fx outflow Rs m2,1338,084 26.4%   
Net fx Rs m6,98848,068 14.5%   
CASH FLOW
From Operations Rs m-2,6956,574 -41.0%  
From Investments Rs m-6,863-7,124 96.3%  
From Financial Activity Rs m12,5455,432 231.0%  
Net Cashflow Rs m3,0101,992 151.1%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 6.9 33.3%  
FIIs % 7.7 34.4 22.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   67,757 56,727 119.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS